NCT01084785

Brief Summary

The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
7.2 years until next milestone

First Submitted

Initial submission to the registry

March 10, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 11, 2010

Completed
16.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

May 13, 2025

Status Verified

May 1, 2025

Enrollment Period

23.3 years

First QC Date

March 10, 2010

Last Update Submit

May 8, 2025

Conditions

Cancer

Keywords

Cancergenomicsproteomics

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary care clinic

You may qualify if:

  • cancer

You may not qualify if:

  • not able to comply with follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht Radiation Oncology

Maastricht, Limburg, Netherlands

RECRUITING

Related Publications (1)

  • Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1.

    PMID: 20888135DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

whole blood

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Dirk De Ruysscher, Prof PHD

    CCMO

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Philippe Lambin, Prof PHD

CONTACT

31 (0) 088 44 55 666philippe.lambin@maastro.nl

Dirk De Ruysscher, Prof PHD

CONTACT

31 (0) 088 44 55 666dirk.deruysscher@maastro.nl

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 10, 2010

First Posted

March 11, 2010

Study Start

January 1, 2003

Primary Completion

May 1, 2026

Study Completion

May 1, 2026

Last Updated

May 13, 2025

Record last verified: 2025-05

Locations

NL(1)